NVO - Weight Loss Drugs By Novo Nordisk Eli Lilly Don't Deter Nestle's Coffee Demand - CEO Explains Why | Benzinga
Nestle S.A. (OTC: NSRGY) CEO Mark Schneider stated that despite the rising use of weight loss medications like Eli Lilly And Company's (NYSE: LLY) Zepbound and Novo Nordisk's (NYSE: NVO) Wegovy, the company has not observed any decrease in coffee consumption.
"Like many others, at Nestle, we have every reason to greet this exciting new class of drugs with optimism," Schneider said in a LinkedIn post.
The executive envisions growth prospects for Nestle in the health science sector, focusing on offering products ...